Barely 2 years old and with three cancer drugs in human testing, San Diego-based Salmedix Inc. is already years ahead of other biotechnology start-ups trying to create new drugs. "There is really only one way to do that," said David S. Kabakoff, Salmedix's cha...

Business Editors NEW YORK--(BUSINESS WIRE)--Oct. 13, 2003 Bioenvision, Inc. (Amex:BIV BiV - BiventricularBIV - BivouacBIV - Bovine Immunodeficiency VirusBIV - Built-in Variable (plumbing)) today announced that its Chairman and CEO, Dr. Christopher B. Wood, will be ...

Business Editors/Health/Medical Writers NEW YORK--(BUSINESS WIRE)--June 17, 2003 Bioenvision, Inc. (OTCBB: BIOV) today announced that it has signed two separate agreements with Ferro Pfanstiehl Laboratories, Inc. for the development and supply of clofarabine, Bioen...

The United States is the first country to approve a single-treatment intravenous drug for hairy cell leukemia, a rare, often fatal cancer of the blood and bone marrow. ...

Definition ...

In what was entitled an "Enforcement Letter," CDER's Division of Drug Marketing, Advertising and Communications (DDMAC) reviewed a mechanism of action (1VIOA) booth panel and handout for Nipent (pentostatin) for Injection and found them to be false or misleading...

Betaseron is approved for use in people with relapsing-remitting MS; the trials that led to its acceptance did not include anyone with any other form of MS. Now, Copolymer I and Bioferon are in their final stages of testing--again, in people who have relapsing-remitt...